Introduction
The third quarter of 2026 underscored just how rapidly the biopharma landscape is being reshaped by capital, innovation, and strategic consolidation. Across July through September, the industry saw a succession of multibillion-dollar acquisitions, high-value licensing agreements, and a broad spectrum of FDA approvals spanning oncology, rare diseases, metabolic disorders, neurology, immunology, and precision diagnostics. …
